How to buy Xenon Pharmaceuticals stock

Xenon Pharmaceuticals Inc is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 123 staff and has a trailing 12-month revenue of around 0.00.

Xenon Pharmaceuticals share price

Use our graph to track the performance of XENE stocks over time.

Xenon Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$7.00 - $21.87
50-day moving average	$16.69
200-day moving average	$13.16
Wall St. target price	$25.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.72

Buy Xenon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Xenon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Xenon Pharmaceuticals Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xenon Pharmaceuticals financials

Revenue TTM	$32.2 million
Gross profit TTM	$-18,357,000
Return on assets TTM	-11.61%
Return on equity TTM	-21.9%
Profit margin	-89.65%
Book value	$4.67
Market capitalisation	$688.3 million

TTM: trailing 12 months

Shorting Xenon Pharmaceuticals shares

There are currently 943,938 Xenon Pharmaceuticals shares held short by investors – that's known as Xenon Pharmaceuticals's "short interest". This figure is 3.4% down from 977,125 last month.

There are a few different ways that this level of interest in shorting Xenon Pharmaceuticals shares can be evaluated.

Xenon Pharmaceuticals's "short interest ratio" (SIR)

Xenon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Xenon Pharmaceuticals shares currently shorted divided by the average quantity of Xenon Pharmaceuticals shares traded daily (recently around 148651.65354331). Xenon Pharmaceuticals's SIR currently stands at 6.35. In other words for every 100,000 Xenon Pharmaceuticals shares traded daily on the market, roughly 6350 shares are currently held short.

However Xenon Pharmaceuticals's short interest can also be evaluated against the total number of Xenon Pharmaceuticals shares, or, against the total number of tradable Xenon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenon Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Xenon Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0287% of the tradable shares (for every 100,000 tradable Xenon Pharmaceuticals shares, roughly 29 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Xenon Pharmaceuticals.

Find out more about how you can short Xenon Pharmaceuticals stock.

Xenon Pharmaceuticals share dividends

We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.

Xenon Pharmaceuticals share price volatility

Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $7 up to $21.869. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.4187. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Xenon Pharmaceuticals overview

Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1. 6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy.

Frequently asked questions

• What percentage of Xenon Pharmaceuticals is owned by insiders or institutions?

  Currently 6.579% of Xenon Pharmaceuticals shares are held by insiders and 81.297% by institutions.

• How many people work for Xenon Pharmaceuticals?

  Latest data suggests 123 work at Xenon Pharmaceuticals.

• When does the fiscal year end for Xenon Pharmaceuticals?

  Xenon Pharmaceuticals's fiscal year ends in December.

• Where is Xenon Pharmaceuticals based?

  Xenon Pharmaceuticals's address is: 200 ? 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8

• What is Xenon Pharmaceuticals's ISIN number?

  Xenon Pharmaceuticals's international securities identification number is: CA98420N1050

• What is Xenon Pharmaceuticals's CUSIP number?

  Xenon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98420N105